middle.news

EMVision Launches Pivotal Trial for emu™ Brain Scanner, Secures $12.58M Cash Buffer

5:44am on Monday 2nd of June, 2025 AEST Healthcare
Read Story

EMVision Launches Pivotal Trial for emu™ Brain Scanner, Secures $12.58M Cash Buffer

5:44am on Monday 2nd of June, 2025 AEST
Key Points
  • Pivotal clinical trial for emu™ bedside brain scanner underway at multiple Australian and US sites
  • First Responder Proof-of-Concept device passes aeromedical testing; further studies approved
  • Continuous Innovation Study ethics approval received to enhance device features alongside pivotal trial
  • Cash reserves stand at $12.58 million as of March 31, 2025, supported by R&D tax rebate and milestone grants
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Emvision Medical Devices (ASX:EMV)
OPEN ARTICLE